Physician

Eric D Batts, M.D.

According to 2025 Medicare claims, Eric Batts, M.D. (NPI: 1821126830) practices hematology/oncology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Ottawa, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 49424-8217. Batts is affiliated with the Trinity Health Integrated Care (ACO ID: A3454) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Batts' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 436 traditional Medicare patients, billed 126,827 HCPCS/CPT codes, and received $2,143,135 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,135 prescription claims across 655 beneficiaries totaling $15,293,780 in drug costs, led by Imbruvica (Ibrutinib). 2022 DME data shows 25 claims. Open Payments data shows 110 records totaling $465,547. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,147,418 and ending at $2,143,135. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,997,669 to $15,293,780. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $39,963 to $6,009.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	559	151,883	$2,147,418
2016	544	169,277	$2,300,225
2017	551	141,765	$2,413,573
2018	547	174,523	$2,557,087
2019	487	127,547	$2,152,522
2020	504	153,512	$3,090,458
2021	420	140,168	$2,244,359
2022	415	118,856	$1,929,795
2023	422	144,040	$1,506,145
2024	436	126,827	$2,143,135

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	390	2,470	$2,997,669
2016	382	2,628	$3,947,509
2017	432	2,947	$4,883,073
2018	451	3,247	$6,522,106
2019	421	3,103	$9,015,550
2020	478	3,487	$9,927,111
2021	485	3,730	$10,319,608
2022	481	4,122	$10,477,443
2023	512	4,178	$9,969,428
2024	655	5,135	$15,293,780

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	362	$105,461
2016	11	289	$59,291
2017	N/R	147	$21,088
2018	N/R	162	$24,971
2019	N/R	57	$8,847
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	25	$952
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	204	423	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	144	182	$56
80053	Blood test, comprehensive group of blood chemicals	218	1,097	$10
36415	Insertion of needle into vein for collection of blood sample	235	1,382	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	226	1,335	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	161	4,560	$2,277,040
Abiraterone Acetate	Abiraterone Acetate	498	14,916	$1,518,618
Revlimid	Lenalidomide	76	2,065	$1,267,900
Xtandi	Enzalutamide	145	4,334	$1,211,279
Cabometyx	Cabozantinib S-Malate	64	1,742	$1,179,979

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$2,035	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	15	$463,512	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eric D. Batts, M.D.?

Tedicare shows public-source Medicare data for Eric D. Batts, M.D. (NPI 1821126830), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eric D. Batts, M.D. have ACO affiliation data?

Eric D. Batts, M.D. is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Eric D. Batts, M.D.?

Eric D. Batts, M.D. is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Eric D. Batts, M.D. have Open Payments data?

Eric D. Batts, M.D. has 110 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.